Eric Lefkofsky is an American entrepreneur best known for being CEO and co-founder of Tempus. Eric joined the University of Michigan where he graduated with honors in 1991. He followed it up with a Juris Doctor from University of Michigan Law School in 1993. Selling of carpets was the first ever business that Eric involved himself in, while still in college. In 2016, Eric Lefkofsky co-founded Tempus.Tempus is a health technology company. Tempus has engineered a system to provide medical data in real-time to physicians to offer the best possible care. With the genomic sequencing offered by Tempus, it plays a vital role in care for cancer patients. It is an operating system built to fight cancer.
With his name behind five successful technology startups, Eric has a great understanding of the business sector. It is why he went on to author a book called Accelerated Disruption. The book focuses on business development and offers critical concepts that would be invaluable to any startup founder. The key concepts mentioned in the book range from capital strategy development to startup promotion.Eric is also a philanthropist. He and his wife Elizabeth started the Lefkofsky Family Foundation in 2006. The aim of this initiative is to enhance the quality of human life through steering high impact programs. Some of these high impact programs are medical research, innovation, and provision of quality education. Eric and Elizabeth’s philanthropy also extends to The Giving Pledge.
This is a campaign encouraging the rich to give a large part of their wealth to philanthropic causes.Regarding serving community interests, Eric is a member of the Children’s Memorial Hospital board of directors. He also holds similar positions at The Museum of Science and Industry and The Art Institute of Chicago. In 2008, he was part of the committee working towards bringing the Summer Olympics to Chicago in 2016.Teaching is also on Eric Lefkofsky’s long CV. He has taught at the Northwestern University as well as DePaul University. Here, he specialized in teaching Applied Technology. He is currently teaching entrepreneurship at the Booth School of Business at the University of Chicago.
Tempus, the cancer fighting start up from extraordinary organizer Eric Lefkofsky, has a goal to give specialists at the University of Chicago, more detailed information on treating patients with breast cancer. Tempus declared an association with the University of Chicago Medicine Thursday in order to give atomic sequencing and investigation to UChicago’s breast cancer specialists. These findings will help them to provide the top individual care for their patients as well as hope for more positive outcomes. Tempus uses real time genomic sequencing to aid in these decisions regarding individual treatment packages. The startup, Tempus, was established in 2015. It is located at 600 W. Chicago, where Groupon, Lightbank, Drivin and Lekofsky’s different endeavors are found.
Eric Lefkofsky is the main supporter and CEO of Tempus. He is an establishing accomplice of Lightbank, a wander support putting resources into problematic innovations. As well as Uptake, EchoLoistics, and Inner Workings. In 2006 he created Lefkofsky Family Foundation with his wife, which is a charity foundation. Eric is also Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago.
Lefkofsky is a subordinate educator at the University of Chicago and creator of Accelerated Disruption. He moved on from the University of Michigan and got his Juris Doctor at University of Michigan Law School. He is a benefactor and Chairman of groupon, a worldwide web based business commercial center, and supporter of Uptake Technologies, a main prescient investigation stage for the world’s biggest companies like Mediaocean. To learn more please follow Lefkofsky on twitter at @lefkofsky and/or facebook at @eplefkofsky. You just have to find his profile at Eric Lefkofsky and you will be able to read his latest stories on the recent findings.
Seattle Genetics is a biotechnology company headquartered in Bothell, Washington. It was incorporated on July 17, 1997 and is listed on the NASDAQ Stock Market. Its main area of business is developing antibody-based therapies for cancer treatments. The treatments involve injecting special antibodies into the body of a cancer patient in order to kill cancer cells.
Currently, the company’s flagship product is Adcetris. This drug is already being sold in at least 50 countries around the world including Canada, the US, Japan and EU member countries. The drug, technically referred to as Brentuximab Vedotin, is the first in a new class of antibody-drug conjugates.
After its incorporation, Seattle Genetics grew fast due to its innovative products. Currently, the company has over 650 employees. Most of these employees are experts in research and development of drugs. Over the years, Seattle Genetics has been involved in different collaborations such as the 2009 collaboration with GlaxoSmithKline, the 2010 collaboration with Genentech, and the 2011 collaboration with Oxford BioTherapeutics. Apart from Adcetris, the company has manufactured other products such as SGN-75, SGN-CD19A, ASG-5ME and ASG-22ME.
The current chief executive officer of the firm is Clay Siegall. He is the founder of the company. He is also the President of the firm and a member of its Board of Directors. In his determination to see the company succeed, Siegall has been involved in different capital raising initiatives such as the 2001 initial public offering. In total, he has been able to raise more than $1.2 billion in capital.
Siegall is an alumnus of the University of Maryland. Here, he graduated with a Bachelor of Science Zoology degree. He received his doctorate in Genetics from The George Washington University. Clay began his professional career at National Cancer Institute in 1988 before joining Bristol-Myers Squibb Pharmaceutical in 1991. He resigned in 1997 to found Seattle Genetics.
Apart from managing Seattle Genetics, Siegall also sits on the boards of several companies. These corporations include Alder Biopharmaceutical, Mirna Therapeutics and Ultragenyx Pharmaceutical. He is also an inventor and an author. Currently, he has 15 patents to his name and at least 70 publications. Most of Siegall’s publications focus on cancer and genetics.
Read More here: